Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$75.07 USD

75.07
2,545,839

+0.59 (0.79%)

Updated May 31, 2024 04:00 PM ET

After-Market: $75.07 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

7 items in cart

View Cart/Checkout

BioMarin Pharmaceutical Inc. [BMRN]

Reports for Purchase

Showing records 541 - 560 ( 814 total )

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 541

08/03/2015

Industry Report

Pages: 48

August and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 542

07/31/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of August 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 543

07/27/2015

Company Report

Pages: 12

Q2 Preview: Consensus Revenues Are Achievable, In Our View; Reiterate Neutral and $130 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 544

07/27/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 545

07/17/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 546

07/17/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 547

07/15/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 548

07/01/2015

Industry Report

Pages: 44

July and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 549

06/30/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 550

06/29/2015

Industry Report

Pages: 7

Regulatory Submissions Moving Ahead as Expected -- 2H15 a Key Determinant of the DMD Landscape

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 551

06/29/2015

Industry Report

Pages: 7

Regulatory Submissions Moving Ahead as Expected -- 2H15 a Key Determinant of the DMD Landscape

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 552

06/25/2015

Daily Note

Pages: 6

EMA Validates BioMarin''s MAA for Drisapersen Ahead of Schedule but with Standard Review; Reiterate $130 PT and NEUTRAL Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 553

06/23/2015

Industry Report

Pages: 7

Looking Backwards and Forwards in the Treatment of DMD

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 554

06/18/2015

Company Report

Pages: 7

BMN-111 (Vosoritide) Achieved a Breakthrough Treating Achondroplasia in Phase 2; Reiterate NEUTRAL for Valuation but Increasing Our PT to $130

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 555

06/08/2015

Daily Note

Pages: 5

Drisapersen MAA Submission Complete; POC BMN 111/Achondroplasia Data Up Next; Reiterate OUTPERFORM and $115 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 556

06/08/2015

Daily Note

Pages: 5

Drisapersen MAA Submission Complete; POC BMN 111/Achondroplasia Data Up Next; Reiterate NEUTRAL and $115 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 557

06/08/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 558

06/02/2015

Industry Report

Pages: 43

Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 559

05/05/2015

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 560

05/04/2015

Industry Report

Pages: 44

May and 2015 Emerging Pharmaceuticals Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party